177 related articles for article (PubMed ID: 11694537)
1. Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb.
Hourcade DE; Mitchell L; Kuttner-Kondo LA; Atkinson JP; Medof ME
J Biol Chem; 2002 Jan; 277(2):1107-12. PubMed ID: 11694537
[TBL] [Abstract][Full Text] [Related]
2. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
Pangburn MK
J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
[TBL] [Abstract][Full Text] [Related]
3. A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases.
Kuttner-Kondo LA; Dybvig MP; Mitchell LM; Muqim N; Atkinson JP; Medof ME; Hourcade DE
J Biol Chem; 2003 Dec; 278(52):52386-91. PubMed ID: 14561755
[TBL] [Abstract][Full Text] [Related]
4. Decay acceleration of the complement alternative pathway C3 convertase.
Hourcade DE; Mitchell LM; Medof ME
Immunopharmacology; 1999 May; 42(1-3):167-73. PubMed ID: 10408377
[TBL] [Abstract][Full Text] [Related]
5. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
Harris CL; Pettigrew DM; Lea SM; Morgan BP
J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
[TBL] [Abstract][Full Text] [Related]
6. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
7. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
Seya T; Holers VM; Atkinson JP
J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
[TBL] [Abstract][Full Text] [Related]
8. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
9. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55).
Harris CL; Abbott RJ; Smith RA; Morgan BP; Lea SM
J Biol Chem; 2005 Jan; 280(4):2569-78. PubMed ID: 15536079
[TBL] [Abstract][Full Text] [Related]
10. Complement alternative pathway activation and control on membranes of human lymphoid B cell lines.
Caudwell V; Porteu F; Calender A; Pangburn MK; Halbwachs-Mecarelli L
Eur J Immunol; 1990 Dec; 20(12):2643-50. PubMed ID: 1702720
[TBL] [Abstract][Full Text] [Related]
11. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase.
Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2009 Jan; 106(3):882-7. PubMed ID: 19136636
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.
Daha MR; Deelder AM; Van Es LA
J Immunol; 1984 May; 132(5):2538-42. PubMed ID: 6232321
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the active sites in decay-accelerating factor.
Kuttner-Kondo LA; Mitchell L; Hourcade DE; Medof ME
J Immunol; 2001 Aug; 167(4):2164-71. PubMed ID: 11490001
[TBL] [Abstract][Full Text] [Related]
14. Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases.
Kuttner-Kondo L; Hourcade DE; Anderson VE; Muqim N; Mitchell L; Soares DC; Barlow PN; Medof ME
J Biol Chem; 2007 Jun; 282(25):18552-18562. PubMed ID: 17395591
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
Daha MR; Kok DJ; Van Es LA
Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
[TBL] [Abstract][Full Text] [Related]
16. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
17. Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H.
Pangburn MK
Immunology; 1990 Dec; 71(4):598-600. PubMed ID: 1703989
[TBL] [Abstract][Full Text] [Related]
18. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B.
Becherer JD; Alsenz J; Esparza I; Hack CE; Lambris JD
Biochemistry; 1992 Feb; 31(6):1787-94. PubMed ID: 1371073
[TBL] [Abstract][Full Text] [Related]
19. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).
Bexborn F; Andersson PO; Chen H; Nilsson B; Ekdahl KN
Mol Immunol; 2008 Apr; 45(8):2370-9. PubMed ID: 18096230
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement.
Pangburn MK; Pangburn KL; Koistinen V; Meri S; Sharma AK
J Immunol; 2000 May; 164(9):4742-51. PubMed ID: 10779780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
